Introduction of escitalopram, a new SSRI in Finland: Comparison of cost-effectiveness between the other SSRIS and SNRI for the treatment of depression and estimation of the budgetary impact

Journal of Medical Economics

Volumn 5, Issue 91-107, 2002, Pages 91-107

  François, Clément ^a   Sintonen, Harri ^b   Toumi, Mondher ^a  

^a Lundbeck   (France)

^b Lundbeck ^*

Author keywords

Depression; Economic; Escitalopram; Models; Pharmacoeconomic analysis

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; NEW DRUG; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ARTICLE; BUDGET; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DEPRESSION; DRUG UTILIZATION; ECONOMICS; FINLAND; HEALTH CARE COST; HUMAN; MODEL; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; REMISSION;

EID: 0141493484     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200205091107     Document Type: Article

References (31)

1. CCOHTA. Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd edn. 1997; Ottawa, Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
2. Finnish Pharmaceuticals Pricing Board. Guidelines for the Preparation of an account of health-economic aspects (an unofficial translation). 1999.
3. Einarson TR, Arikian S, Sweeney S et al. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clinical Therapeutics 1995; 17: 136-153.
4. Lapierre Y, Bentkover J, Schainbaum, S et al. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Canadian Journal of Psychiatry 1995; 40: 370-377.
5. Nuijten MJ, Hardens M, Souetre E. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics 1995; 8: 159-168.
6. Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997; 12: 286-296.
7. Buxton MJ, Drummond MF, Van Hout BA et al. Modelling in economic evaluation: an unavoidable fact of life [editorial] [see comments]. Health Economics 1997; 6: 217-227.
8. Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000; 157 (Suppl): 1-45.
9. Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 2000; 14: 3-20.
10. Burke WJ, Gergel, Bose A. Fixed dose trial of the single isomer SSRI escitalopram in dpressed outpatients. Journal of Clinical Psychiatry 2002; 63: 331-336.
11. Patris M, Bouchard JM, Bougerol T et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. International Clinical Psychopharmacology 1996; 11: 129-136.
12. Bougerol T, Scotto JC, Patris M. Citalopram and fluoxetine in major depression: comparison of two clinical trials in a psychiatrist setting and in general practice. Clinical Drug Investigation 1997; 14: 77-89.
13. Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression [see comments]. Journal of Clinical Psychiatry 1998; 59: 352-357.
14. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of Affective Disorders 1999; 56: 171-181.
15. Dierick M, Ravizza L, Realini R et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuropsychopharmacology and Biological Psychiatry 1996; 20: 57-71.
16. Diaz-Martinez A, Benassinni O, Ontiveros A et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clinical Therapeutics 1998; 20: 467-476.
17. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. International Clinical Psychopharmacology 1993; 8: 181-188.
18. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. International Clinical Psychopharmacology 1995; 10 (Suppl. 1): 29-35.
19. Reimherr FW, Amsterdam JD, Quitkin FM et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. American Journal of Psychiatry 1998; 155: 1247-1253.
20. Entsuah AR, Rudolph RL, Hackett D et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. International Clinical Psychopharmacology 1996; 11: 137-145.
21. Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. Journal of Clinical Psychiatry 2001; 62: 135-142.
22. Kiloh LG, Andrews G, Neilson M. The long-term outcome of depressive illness. British Journal of Psychiatry 1988; 153: 752-775.
23. Thornicroft G, Sartorius N. The course and outcome of depression in different cultures: 10-year follow-up of the WHO Collaborative Study on the Assessment of Depressive Disorders. Psychological Medicine 1993; 23: 1023-1032.
24. Angst J, Preisig M. Outcome of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz. Archives of Neurology and Psychiatry 1995; 146: 17-23.
25. Statistical yearbook of the Social Insurance Institution, Finland 2000. Publication T1:36, Helsinki 2001.
26. Heikkinen et al. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2000. Stakes Aiheita 23/2001, Helsinki 2001.
27. Statistics Finland, http://statfin.stat.fi/statweb/
28. Straton JB, Cronholm P. Are paroxetine, fluoxetine, and sertraline equally effective for depression? Journal of Family Practice 2002; 51: 285.
29. Kroenke K, West SL, Swindle R et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. Journal of the American Medical Association 2001; 286: 2947-2955.
30. Palmer CS, Revicki DA, Genduso LA et al. A cost-effectiveness clinical decision analysis model for schizophrenia. American Journal of Managed Care 1998; 4: 345-355.
31. Runeson B, Wasserman D. Management of suicide attempters: what are the routines and the costs? Acta Psychiatrica Scandinavica 1994; 90: 222-228.